Amber Implants’ VCFix spine system for vertebral compression fractures showed clinical improvements in one-year follow-ups in its first human clinical trial.
No trial participants had device-related adverse events after a year, and there were “significant” improvements in key clinical performance outcomes, according to a June 3 news release.
By the six-month follow up, pain scores decreased by more than eight points, and disability scores showed an 84-point reduction from baseline. Those results were maintained through the one-year follow-up period.
Amber Implants is preparing clinical trials at multiple sites in Europe, including two centers in the first clinical study.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
